<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADIPEX-P- phentermine hydrochloride tablet </strong><br>A-S Medication Solutions LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ADIPEX-P<span class="Sup">®</span> safely and effectively.  See full prescribing information for ADIPEX-P<span class="Sup">®</span>.<br>ADIPEX-P<span class="Sup">®</span> (phentermine hydrochloride USP) for oral use                                                         CIV<br>Initial U.S. Approval: 1959</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ADIPEX-P<span class="Sup">®</span> is a sympathomimetic amine <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> for patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index ≥ 30 kg/m<span class="Sup">2</span>, or ≥ 27 kg/m<span class="Sup">2</span> in the presence of other risk factors (e.g., controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>). (<a href="#i4i_indications_id_852c6f5f-ec7a-455c-93fc-fcfab0fb29e0">1</a>) </p>
<p class="Highlighta">The limited usefulness of agents of this class, including ADIPEX-P<span class="Sup">®</span>, should be measured against possible risk factors inherent in their use. (<a href="#i4i_indications_id_852c6f5f-ec7a-455c-93fc-fcfab0fb29e0">1</a>)  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Dosage should be individualized to obtain an adequate response with the lowest effective dose. (<a href="#i4i_dosage_admin_id_6296bd7c-5497-4d47-be00-6474ab1247b6">2</a>)</li>
<li>Late evening administration should be avoided (risk of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>). (<a href="#i4i_dosage_admin_id_6296bd7c-5497-4d47-be00-6474ab1247b6">2</a>)</li>
<li>ADIPEX-P<span class="Sup">®</span> can be taken with or without food. (<a href="#i4i_pharmacokinetics_id_981fef3d-6de1-4377-a202-c007f5e8cf71">12.3</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Capsules containing 37.5 mg phentermine hydrochloride. (<a href="#i4i_dosage_form_strength_id_cdab3487-c7fa-446c-9fb3-446b3ecccd55">3</a>)</li>
<li>Tablets containing 37.5 mg phentermine hydrochloride. (<a href="#i4i_dosage_form_strength_id_cdab3487-c7fa-446c-9fb3-446b3ecccd55">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>History of cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>) (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li>During or within 14 days following the administration of monoamine oxidase inhibitors (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li>History of drug abuse (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>)</li>
<li>Pregnancy (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>, <a href="#i4i_pregnancy_id_3a40586f-428e-4425-8acd-eb602c8c97c7">8.1</a>)</li>
<li>Nursing (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>, <a href="#i4i_nursing_mothers_id_4188225d-fc3a-4739-81b4-070de0550b09">8.3</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, or idiosyncrasy to the sympathomimetic amines (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Coadministration with other drugs for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is not recommended (safety and efficacy of combination not established). (<a href="#i4i_section_id_749c7d9b-3fd2-4ef7-9008-8e7eb9a2c098">5.1</a>)</li>
<li>Rare cases of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> have been reported. ADIPEX-P<span class="Sup">®</span> should be discontinued in case of new, unexplained symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. (<a href="#i4i_section_id_3cbb452d-69ce-4d95-a35a-ca2bf6b60cf4">5.2</a>) </li>
<li>Rare cases of serious regurgitant cardiac valvular disease have been reported. (<a href="#i4i_section_id_31d11ea2-9050-48ea-9b6a-f39852f40c30">5.3</a>) </li>
<li>Tolerance to the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effect usually develops within a few weeks. If this occurs, ADIPEX-P<span class="Sup">®</span> should be discontinued. The recommended dose should not be exceeded. (<a href="#i4i_section_id_5a6be101-0c79-4a96-af6a-ec3f62c521fc">5.4</a>) </li>
<li>ADIPEX-P<span class="Sup">®</span> may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. (<a href="#i4i_section_id_208f9f1a-2773-484b-acb9-ce27e8afffd8">5.5</a>) </li>
<li>Risk of abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. (<a href="#i4i_section_id_fd5d3a8b-6378-4326-a539-ee743e9ca2a5">5.6</a>) </li>
<li>Concomitant alcohol use may result in an adverse drug reaction. (<a href="#i4i_section_id_9678c074-c13f-4cd0-b8fe-dd236488f3b5">5.7</a>)</li>
<li>Use caution in patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (risk of increase in blood pressure). (<a href="#i4i_section_id_b1a76d15-a960-4977-9412-5643f4293c18">5.8</a>)</li>
<li>A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (<a href="#i4i_section_id_4d96eb5a-522d-4327-a7f3-6ae7e1d42084">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (<a href="#i4i_adverse_effects_id_048a7320-7dcf-4972-86b6-8a415b0a54c8">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Monoamine oxidase inhibitors: Risk of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>, <a href="#i4i_section_id_acb74ae3-d33a-4616-a430-4de3aed1ad1c">7.1</a>)</li>
<li>Alcohol: Consider potential interaction (<a href="#i4i_section_id_5bee9036-0753-4c15-97f8-e2c7a77916d5">7.2</a>)</li>
<li>Insulin and oral hypoglycemics: Requirements may be altered. (<a href="#i4i_section_id_7f86b684-829d-4c08-8302-477c6433851c">7.3</a>)</li>
<li>Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by ADIPEX-P<span class="Sup">®</span>. (<a href="#i4i_section_id_bac0a416-f0e9-4c55-a00f-8ae6bc698b81">7.4</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>, <a href="#i4i_nursing_mothers_id_4188225d-fc3a-4739-81b4-070de0550b09">8.3</a>)</li>
<li>Pediatric use: Safety and effectiveness not established. (<a href="#i4i_pediatric_use_id_64e566af-a513-4f50-9302-fa306e12cc3d">8.4</a>)</li>
<li>Geriatric use: Due to substantial renal excretion, use with caution. (<a href="#i4i_geriatric_use_id_a97fe78e-9c5b-41fe-a29c-17c7a777323c">8.5</a>)</li>
<li>Use caution when administering ADIPEX-P<span class="Sup">®</span> to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#i4i_section_id_1921387d-0173-474e-af53-9ec811998306">8.6</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Coadministration With Other Drug Products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular Heart Disease</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Development of Tolerance, Discontinuation in Case of Tolerance </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Risk of Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Usage With Alcohol </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Use in Patients With <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Alcohol </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Insulin and Oral Hypoglycemic Medications </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Adrenergic Neuron Blocking Drugs </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Acute Overdosage </a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span> </a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">HOW SUPPLIED</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ADIPEX-P<span class="Sup">®</span> is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> for patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index ≥ 30 kg/m<span class="Sup">2</span>, or ≥ 27 kg/m<span class="Sup">2</span> in the presence of other risk factors (e.g., controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>).</p>
<p>Below is a chart of body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) based on various heights and weights.</p>
<p>BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.</p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b335e637-dca3-45c8-ad12-7eb03be2caaa&amp;name=e941ec20-b605-4e03-9002-052a52a71b12-01.jpg"></div>
<p>The limited usefulness of agents of this class, including ADIPEX-P<span class="Sup">®</span>, [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_mechanism_action_id_15dfed97-801d-4be9-ace1-ec1fc293b28c">12.1</a>, <a href="#i4i_pharmacodynamics_id_e6f4671f-9a1b-4203-a1cd-5bf320ff9d77">12.2</a>)</span>] should be measured against possible risk factors inherent in their use such as those described below. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> </span></p>
<p>Dosage should be individualized to obtain an adequate response with the lowest effective dose. </p>
<p>The usual adult dose is one capsule (37.5 mg) daily as prescribed by the physician, administered before breakfast or 1 to 2 hours after breakfast for appetite control. </p>
<p>The usual adult dose is one tablet (37.5 mg) daily, as prescribed by the physician, administered before breakfast or 1 to 2 hours after breakfast. The dosage may be adjusted to the patient’s need. For some patients, half tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give half tablets (18.75 mg) two times a day.</p>
<p>ADIPEX-P<span class="Sup">®</span> is not recommended for use in pediatric patients ≤ 16 years of age.</p>
<p>Late evening medication should be avoided because of the possibility of resulting <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base).</p>
<p>Tablets containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul>
<li>History of cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>)</li>
<li>During or within 14 days following the administration of monoamine oxidase inhibitors</li>
<li><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></li>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states</li>
<li>History of drug abuse</li>
<li>Pregnancy [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_3a40586f-428e-4425-8acd-eb602c8c97c7">8.1</a>)</span>]</li>
<li>Nursing [<span class="Italics">see Use in Specific Populations (<a href="#i4i_nursing_mothers_id_4188225d-fc3a-4739-81b4-070de0550b09">8.3</a>)</span>] </li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, or idiosyncrasy to the sympathomimetic amines </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Coadministration With Other Drug Products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span> </h2>
<p class="First"><span class="Bold">ADIPEX-P<span class="Sup">®</span> is indicated only as short-term (a few weeks) monotherapy for the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. The safety and efficacy of combination therapy with ADIPEX-P<span class="Sup">®</span> and any other drug products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of ADIPEX-P<span class="Sup">®</span> and these drug products is not recommended. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span> </h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span> (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of ADIPEX-P<span class="Sup">®</span> alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone.</span> The initial symptom of PPH is usually <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Other initial symptoms may include <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and patients should be evaluated for the possible presence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular Heart Disease</span> </h2>
<p class="First"><span class="Bold">Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> and the use of ADIPEX-P<span class="Sup">®</span> alone cannot be ruled out; there have been rare cases of <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> in patients who reportedly have taken phentermine alone. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 Development of Tolerance, Discontinuation in Case of Tolerance </h2>
<p class="First">When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks </h2>
<p class="First">ADIPEX-P<span class="Sup">®</span> may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6 Risk of Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </h2>
<p class="First">ADIPEX-P<span class="Sup">®</span> is related chemically and pharmacologically to amphetamine (d- and d<span class="Italics">l</span>l-amphetamine) and other related stimulant drugs that have been extensively abused.  The possibility of abuse of ADIPEX-P<span class="Sup">®</span> should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#i4i_abuse_dependence_id_a1ac2e98-84f0-4b24-ab3f-30638f5e544c">9</a>)</span> and <span class="Italics">Overdosage (<a href="#i4i_overdosage_id_345dbbb0-d6a2-4c02-bcea-44e3d0237f5b">10</a>)</span>. </p>
<p>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>5.7 Usage With Alcohol </h2>
<p class="First">Concomitant use of alcohol with ADIPEX-P<span class="Sup">®</span> may result in an adverse drug reaction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>5.8 Use in Patients With <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </h2>
<p class="First">Use caution in prescribing ADIPEX-P<span class="Sup">®</span> for patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (risk of increase in blood pressure). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </h2>
<p class="First">A reduction in insulin or oral hypoglycemic medications in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may be required. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described, or described in greater detail, in other sections: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary pulmonary hypertension</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_3cbb452d-69ce-4d95-a35a-ca2bf6b60cf4">5.2</a>)</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_31d11ea2-9050-48ea-9b6a-f39852f40c30">5.3</a>)</span>] </li>
<li>Effect on the ability to engage in potentially hazardous tasks [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_208f9f1a-2773-484b-acb9-ce27e8afffd8">5.5</a>)</span>] </li>
<li>Withdrawal effects following prolonged high dosage administration [<span class="Italics">see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#i4i_dependence_id_2a9b512b-6561-4472-9a28-c24daa1ee962">9.3</a>)</span>] </li>
</ul>
<p>                                                                                                                                                       The following adverse reactions to phentermine have been identified: </p>
<p><span class="Underline">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary pulmonary hypertension</span> and/or regurgitant cardiac valvular disease, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevation of blood pressure, ischemic events. </p>
<p><span class="Underline">Central Nervous System</span></p>
<p>Overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p><span class="Underline">Gastrointestinal</span></p>
<p>Dryness of the mouth, unpleasant taste, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, other <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.</p>
<p><span class="Underline">Allergic</span></p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>.</p>
<p><span class="Underline">Endocrine</span></p>
<p><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, changes in libido. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors </h2>
<p class="First">Use of ADIPEX-P<span class="Sup">®</span> is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 Alcohol </h2>
<p class="First">Concomitant use of alcohol with ADIPEX-P<span class="Sup">®</span> may result in an adverse drug reaction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 Insulin and Oral Hypoglycemic Medications </h2>
<p class="First">Requirements may be altered [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_4d96eb5a-522d-4327-a7f3-6ae7e1d42084">5.9</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>7.4 Adrenergic Neuron Blocking Drugs </h2>
<p class="First">ADIPEX-P<span class="Sup">®</span> may decrease the hypotensive effect of adrenergic neuron blocking drugs.  </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"> </p>
<p><span class="Italics">Teratogenic Effects </span></p>
<p><span class="Underline">Pregnancy category X</span></p>
<p>ADIPEX-P<span class="Sup">®</span> is contraindicated during pregnancy because <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and no <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and d<span class="Italics">l</span>l-amphetamine) [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_mechanism_action_id_15dfed97-801d-4be9-ace1-ec1fc293b28c">12.1</a>)</span>]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if ADIPEX-P<span class="Sup">®</span> is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Because pediatric <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.  </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">ADIPEX-P<span class="Sup">®</span> was not studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Use caution when administering ADIPEX-P<span class="Sup">®</span> to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_981fef3d-6de1-4377-a202-c007f5e8cf71">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Phentermine is a Schedule IV controlled substance. </p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. </p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Abuse of amphetamines and related drugs may be associated with intense psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG. Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. A severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>10.1 Acute Overdosage </h2>
<p class="First">Manifestations of acute overdosage include <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, rapid respiration, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, assaultiveness, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and panic states. <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation. Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. Overdosage of pharmacologically similar compounds has resulted in fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and usually terminates in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. </p>
<p>Management of acute phentermine hydrochloride <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine<span class="Sup">®</span>, CIBA) has been suggested on pharmacologic grounds for possible acute, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, if this complicates overdosage. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>10.2 Chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span> </h2>
<p class="First">Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. See <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#i4i_dependence_id_2a9b512b-6561-4472-9a28-c24daa1ee962">9.3</a>)</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Phentermine hydrochloride USP is a sympathomimetic amine <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span>. It has the chemical name of α,α,-Dimethylphenethylamine hydrochloride. The structural formula is as follows:</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b335e637-dca3-45c8-ad12-7eb03be2caaa&amp;name=e941ec20-b605-4e03-9002-052a52a71b12-02.jpg"></div>
<p>C<span class="Sub">10</span>H<span class="Sub">15</span>N•HCl          M.W. 185.7</p>
<p>Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.</p>
<p>ADIPEX-P<span class="Sup">®</span>, an <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agent for oral administration, is available as a capsule or tablet containing 37.5 mg of phentermine hydrochloride (equivalent to 30 mg of phentermine base).</p>
<p>ADIPEX-P<span class="Sup">®</span> Capsules contain the inactive ingredients Black Iron Oxide, Corn Starch, D&amp;C Red #33, FD&amp;C Blue #1, Gelatin, Lactose Monohydrate, Magnesium Stearate, Propylene Glycol, Shellac, and Titanium Dioxide.</p>
<p>ADIPEX-P<span class="Sup">®</span> Tablets contain the inactive ingredients Corn Starch, Lactose (Anhydrous), Magnesium Stearate, Microcrystalline Cellulose, Pregelatinized Starch, Sucrose, and FD&amp;C Blue #1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ADIPEX-P<span class="Sup">®</span> is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, amphetamine (d- and d<span class="Italics">l</span>l-amphetamine). Drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> are commonly known as “anorectics? or “anorexigenics.? It has not been established that the primary action of such drugs in treating <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is one of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite suppression</span> since other central nervous system actions, or metabolic effects, may also be involved. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span> and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following the administration of phentermine, phentermine reaches peak concentrations (C<span class="Sub">max</span>) after 3 to 4.4 hours. </p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></p>
<p>ADIPEX-P<span class="Sup">®</span> was not studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62% to 85%. Exposure increases can be expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Use caution when administering ADIPEX-P<span class="Sup">®</span> to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  </p>
<p><span class="Underline">Drug Interactions</span></p>
<p>In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine C<span class="Sub">max</span> and AUC increase 13% and 42%, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with “anorectic? drugs lost more weight on the average than those treated with placebo and diet. </p>
<p>The magnitude of increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> due to the various drug effects are not established. The amount of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> associated with the use of an “anorectic? drug varies from trial to trial, and the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. </p>
<p>The natural history of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is measured over several years, whereas the studies cited are restricted to a few weeks’ duration; thus, the total impact of drug-induced <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> over that of diet alone must be considered clinically limited. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_HOWSUPPLIED"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table border="0" cellpadding="1" cellspacing="1">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" valign="bottom"><p class="First">Repackaged by A-S Medication Solutions - Libertyville, IL<br>See <span class="Bold Italics"><a href="#Repack">REPACKAGING INFORMATION</a></span> for available configurations.</p></td></tr>
<tr class="Last"><td align="left" valign="bottom"><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b335e637-dca3-45c8-ad12-7eb03be2caaa&amp;name=ASMLogo.jpg"></td></tr>
</tbody>
</table>
<p class="First">Available in tablets and capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base). Each blue and white, oblong, speckled, scored tablet is debossed with “ADIPEX-P? and “9?-“9?. The #3 capsule has an opaque white body and an opaque bright blue cap. Each capsule is imprinted with “ADIPEX-P? - “37.5? on the cap and two stripes on the body using dark blue ink.</p>
<p>Tablets are packaged in bottles of 30 (NDC 57844-009-56); 100 (NDC 57844-009-01); and 1000 (NDC 57844-009-10).</p>
<p>Capsules are packaged in bottles of 100 (NDC 57844-019-01).</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients must be informed that ADIPEX-P<span class="Sup">®</span> is a <span class="Italics">short-term</span> (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and that coadministration of phentermine with other drugs for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is not recommended [<span class="Italics">see Indications and Usage (<a href="#i4i_indications_id_852c6f5f-ec7a-455c-93fc-fcfab0fb29e0">1</a>) and Warnings and Precautions (<a href="#i4i_warnings_precautions_id_542fd7a6-152b-4c82-971e-e22cbbf27ef0">5</a>)</span>]. </p>
<p>Patients must be instructed on how much ADIPEX-P<span class="Sup">®</span> to take, and when and how to take it [<span class="Italics">see Dosage and Administration (<a href="#i4i_dosage_admin_id_6296bd7c-5497-4d47-be00-6474ab1247b6">2</a>)</span>]. </p>
<p>Advise pregnant women and nursing mothers not to use ADIPEX-P<span class="Sup">®</span> [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_3a40586f-428e-4425-8acd-eb602c8c97c7">8.1</a>, <a href="#i4i_nursing_mothers_id_4188225d-fc3a-4739-81b4-070de0550b09">8.3</a>)</span>]. </p>
<p>Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:  </p>
<ul>
<li>Development of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span>  [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_3cbb452d-69ce-4d95-a35a-ca2bf6b60cf4">5.2</a>)</span>] </li>
<li>Development of serious <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>  [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_31d11ea2-9050-48ea-9b6a-f39852f40c30">5.3</a>)</span>] </li>
<li>Effects on the ability to engage in potentially hazardous tasks  [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_208f9f1a-2773-484b-acb9-ce27e8afffd8">5.5</a>)</span>] </li>
<li>The risk of an increase in blood pressure [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_b1a76d15-a960-4977-9412-5643f4293c18">5.8</a>) and Adverse Reactions (<a href="#i4i_adverse_effects_id_048a7320-7dcf-4972-86b6-8a415b0a54c8">6</a>)</span>] </li>
<li>The risk of interactions [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_2a58c010-35e4-476e-8f19-a9998626490f">4</a>), Warnings and Precautions (<a href="#i4i_warnings_precautions_id_542fd7a6-152b-4c82-971e-e22cbbf27ef0">5</a>) and Drug Interactions (<a href="#i4i_interactions_id_6e2a51f0-75c8-4471-991d-88558623f81b">7</a>)</span>] </li>
</ul>
<p>See also, for example, <span class="Italics">Adverse Reactions (<a href="#i4i_adverse_effects_id_048a7320-7dcf-4972-86b6-8a415b0a54c8">6</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#i4i_specific_populations_id_986a6bd6-1c8c-4fc2-97b0-b39f6901dddc">8</a>)</span>. </p>
<p>The patients must also be informed about </p>
<ul>
<li>the potential for developing tolerance and actions if they suspect development of tolerance  [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_5a6be101-0c79-4a96-af6a-ec3f62c521fc">5.4</a>)</span>] and </li>
<li>the risk of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the potential consequences of abuse [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_fd5d3a8b-6378-4326-a539-ee743e9ca2a5">5.6</a>), Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#i4i_abuse_dependence_id_a1ac2e98-84f0-4b24-ab3f-30638f5e544c">9</a>), and Overdosage (<a href="#i4i_overdosage_id_345dbbb0-d6a2-4c02-bcea-44e3d0237f5b">10</a>)</span>]. </li>
</ul>
<p>Tell patients to keep ADIPEX-P<span class="Sup">®</span> in a safe place to prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, misuse or abuse. Selling or giving away ADIPEX-P<span class="Sup">®</span> may harm others and is against the law.</p>
<p>All trademarks are the property of their respective owners.</p>
<p>Manufactured by:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA </span></p>
<p>Sellersville, PA 18960</p>
<p>Manufactured for:</p>
<p><span class="Bold">Teva Select Brands</span>, Horsham, PA 19044</p>
<p>Division of Teva Pharmaceuticals USA</p>
<p>Rev. X 1/2013</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Repack"></a><a name="section-17"></a><p></p>
<h1>REPACKAGING INFORMATION</h1>
<p class="First">Please reference the <span class="Bold Italics"><a href="#LINK_HOWSUPPLIED">HOW SUPPLIED</a></span> section listed above for a description of individual tablets or capsules.  This drug product has been received by A-S Medication Solutions - Libertyville, IL in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations.  The package configurations available from A-S Medication Solutions are listed below:</p>
<table border="0" cellpadding="1" cellspacing="1" width="46%">
<colgroup>
<col width="18%">
<col width="10%">
<col width="18%">
</colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Bold" align="center" valign="bottom">NDC#</td>
<td align="center" valign="bottom"><span class="Bold">Count</span></td>
<td align="center" valign="bottom"><span class="Bold">Strength</span></td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">50090-0284-0</td>
<td align="center">30</td>
<td align="center">37.5 mg</td>
</tr>
</tbody>
</table>
<p>
                     Repackaged by:<br><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b335e637-dca3-45c8-ad12-7eb03be2caaa&amp;name=ASMLogo.jpg"><br>Libertyville, IL 60048</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50090-0284-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="50090-0284-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b335e637-dca3-45c8-ad12-7eb03be2caaa&amp;name=50090-0284-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADIPEX-P 		
					</strong><br><span class="contentTableReg">phentermine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50090-0284(NDC:57844-009)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENTERMINE HYDROCHLORIDE</strong> (PHENTERMINE) </td>
<td class="formItem">PHENTERMINE HYDROCHLORIDE</td>
<td class="formItem">37.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ADIPEX;P;9;9</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50090-0284-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085128</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">repack(50090-0284)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d4bae49b-2220-433c-ad6f-463ed6059cfc</div>
<div>Set id: b335e637-dca3-45c8-ad12-7eb03be2caaa</div>
<div>Version: 1</div>
<div>Effective Time: 20141215</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
